23412-95-5

Basic information

• Product Name: DL-Erythro-2-amino-1,2-diphenylethanol
• Synonyms: (1S,2R)-1,2-Diphenyl-2-hydroxyethylamine;DL-Erythro-2-amino-1,2-diphenylethanol
• CAS NO: 23412-95-5
• Molecular Formula: C₁₄H₁₅NO
• Molecular Weight: 213.275
• Mol File: 23412-95-5.mol
• Article Data: 50

Chemical Properties

• Melting Point: 163-165℃
• Boiling Point: 374.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.148
• PKA: 11.70±0.45(Predicted)
• CAS DataBase Reference: DL-Erythro-2-amino-1,2-diphenylethanol(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Erythro-2-amino-1,2-diphenylethanol(23412-95-5)
• EPA Substance Registry System: DL-Erythro-2-amino-1,2-diphenylethanol(23412-95-5)

Safety Data

• Hazardous Substances Data: 23412-95-5(Hazardous Substances Data)

Usage

General Description

DL-Erythro-2-amino-1,2-diphenylethanol, also known as phenyltoloxamine, is a chemical compound with a molecular formula C14H15NO. It is a stereoisomer of threo-2-amino-1-phenylpropan-1-ol and is used as an antihistamine and anticholinergic medication. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. Phenyltoloxamine is commonly used to relieve symptoms of allergy, hay fever, and the common cold, as well as to treat motion sickness. It is also used in combination with other drugs for the treatment of pain and cough. Additionally, it has been investigated for its potential as an antidepressant and has shown some efficacy in preclinical studies.

Upstream product

• 64-17-5 ethanol 
• 87-69-4 L-Tartaric acid 
• 530-36-9 threo-1,2-diphenyl-2-aminoethan-1-ol 
• 574-15-2 benzilmonoxime 
• 3723-23-7 2-amino-1,2-diphenylethanone 
• 100-52-7 benzaldehyde 
• 530-36-9 2-amino-1,2-diphenylethanol 
• 131350-15-7 N-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]formamide 
• 91840-94-7 (R)-(-)-(E)-1,2-Diphenyl-2-(hydroxyimino)ethanol 
• 7664-93-9 sulfuric acid 
• 184674-48-4 (+)-(2R,3R)-trans-2,3-diphenylaziridine 
• 23364-44-5 (1S,2R)-2-Amino-1,2-diphenylethanol 
• 39664-88-5 N-[(1S,2R)-2-hydroxy-1,2-diphenylethyl]formamide 
• 2935-35-5 (S)-2-phenylglycine 

Downstream Products

• 6275-45-2 dichloro-acetic acid-(α'-hydroxy-bibenzyl-α-ylamide) 
• 530-36-9 (1R,2R)-2-amino-1,2-diphenylethane-1-ol 
• 492-70-6 1,2-diphenyl-1,2-ethanediol 
• 530-36-9 (1S,2S)-2-amino-1,2-diphenylethanol 
• 530-36-9 2-amino-1,2-diphenylethanol 
• 6287-74-7 (+/-)-erythro-α'-(2-diethylamino-ethylamino)-bibenzyl-α-ol 
• 23364-44-5 (1S,2R)-2-Amino-1,2-diphenylethanol 
• 23190-16-1 (1R,2S)-2-Amino-1,2-diphenylethanol 
• 530-36-9 threo-1,2-diphenyl-2-aminoethan-1-ol 
• 49855-40-5 (+/-)-erythro-α'-chloro-bibenzylyl-(α)-amine 
• 49855-40-5 (+/-)-threo-α'-chloro-bibenzylyl-(α)-amine 
• 780-25-6 N-benzylidene benzylamine 
• 100-52-7 benzaldehyde 
• 100-46-9 benzylamine 

Relevant articles and documents

Site-Specific C(sp3)–H Aminations of Imidates and Amidines Enabled by Covalently Tethered Distonic Radical Anions

The utilization of N-centered radicals to synthesize nitrogen-containing compounds has attracted considerable attention recently, due to their powerful reactivities and the concomitant construction of C?N bonds. However, the generation and control of N-centered radicals remain particularly challenging. We report a tethering strategy using SOMO-HOMO-converted distonic radical anions for the site-specific aminations of imidates and amidines with aid of the non-covalent interaction. This reaction features a remarkably broad substrate scope and also enables the late-stage functionalization of bioactive molecules. Furthermore, the reaction mechanism is thoroughly investigated through kinetic studies, Raman spectroscopy, electron paramagnetic resonance spectroscopy, and density functional theory calculations, revealing that the aminations likely involve direct homolytic cleavage of N?H bonds and subsequently controllable 1,5 or 1,6 hydrogen atom transfer.

Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics

Key building blocks for the production of fully synthetic macrolides have been scaled-up in first time pilot plant and kilo-lab campaigns. These building blocks have supported the discovery of new macrolide antibiotics as well as ongoing preclinical studies.

HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).